Simple Summary Breast cancer is the most common cancer among women. It is estimated
that 2.3 million new cases of BC are diagnosed globally each year. Based on mRNA gene …

Triple‑negative breast cancer (TNBC) accounts for 10‑15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …

This article is the American Cancer Society's update on female breast cancer statistics in the
United States, including population‐based data on incidence, mortality, survival, and …

Importance Coping with the current and future burden of cancer requires an in-depth
understanding of trends in cancer incidences and deaths. Estimated projections of cancer …

Background Sacituzumab govitecan demonstrated significant progression-free survival
benefit over chemotherapy in the phase 3 TROPiCS-02 trial in patients with pretreated …

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a
prostate cancer diagnosis and include management options for localized, regional, and …

Abstract Each year, the American Cancer Society estimates the numbers of new cancer
cases and deaths that will occur in the United States and compiles the most recent data on …

Background Standard chemotherapy is associated with low response rates and short
progression-free survival among patients with pretreated metastatic triple-negative breast …

Triple-negative breast cancer accounted for 12% of breast cancers diagnosed in the United
States from 2012 to 2016, with a 5-year survival 8% to 16% lower than hormone receptor …

BACKGROUND The American Cancer Society (ACS), the Centers for Disease Control and
Prevention (CDC), the National Cancer Institute (NCI), and the North American Association …